查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718160

双特异性抗体市场（按作用机制、治疗领域和最终用户划分）—2025-2030 年全球预测

Bispecific Antibodies Market by Mechanism of Action, Therapeutic Area, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年双特异性抗体市值为 57.1 亿美元，预计 2024 年将成长至 74.9 亿美元，复合年增长率为 32.64%，预计到 2030 年将达到 412.9 亿美元。

主要市场统计数据
基准年2023年 57.1亿美元
预计2024年 74.9亿美元
预测年份 2030 412.9亿美元
复合年增长率（%） 32.64%

双特异性抗体正迅速成为突破性治疗方法，重新定义多个疾病领域的治疗范例。在当今精准和有针对性的干预至关重要的环境下，这种创新药物处于生物医学的前沿。设计同时针对两种不同抗原的抗体的科学已取得重大进展，比传统治疗方法具有更高的特异性和有效性。本报告对双特异性抗体市场进行了深入分析，探讨了市场驱动因素、技术突破和不断发展的市场策略。透过检验临床进展和潜在的分子机制，我们将双特异性抗体的治疗潜力置于现代医学的更广泛背景中。它面向寻求了解这一动态领域的影响和未来发展轨蹟的行业专业人士和关键决策者，重点关注影响决策的策略和管理方面。这篇综合评论表明，双特异性抗体在重塑各种治疗应用的治疗策略方面具有巨大的价值，并且在市场上发展势头强劲。

改变双特异性抗体市场

双特异性抗体市场正在经历变革时期，其驱动力是重塑临床和商业策略的关键进展。技术进步加速了这些复杂分子的发现和优化，最终透过复杂的分子工程实现了与目标抗原的增强结合。监管方法也在不断发展，在快速上市途径和严格的安全评估之间取得平衡，以保持高标准。製药公司和生物技术创新者之间的策略联盟进一步推动了这种转变，形成了一个竞争而又共生的生态系统，加速了临床试验以及从实验室到临床的转变。对自适应临床设计和强大数据分析的投资揭示了重要的功效和安全性，使公司能够改善患者选择并最大限度地提高治疗效果。这种不断发展的格局的特点是科学发现、不断发展的监管格局和市场适应之间的动态相互作用，凸显了相关人员在快速变化的环境中保持知情并采取灵活行动的必要性。透过利用这些变革性转变，产业领导者可以充分利用双特异性抗体的潜力来推动有意义的临床进展。

关键细分洞察

详细的細項分析可以更深入地了解双特异性抗体市场，阐明有针对性的干预途径，并揭示成长机会。基于机制的市场研究表明，双抗原靶向、双阻断抗体和 T 细胞接合剂等方法在塑造治疗结果和市场动态方面发挥关键作用。同时，基于治疗领域的细分显示，从自体免疫疾病和感染疾病到神经系统疾病和肿瘤等多种疾病都是临床应用的关键驱动因素。这种多方面的方法使相关人员能够精确定位未满足需求最大的领域，以及与新兴临床证据最相符的潜在收益来源。此外，透过区分医院和专科诊所的应用以及研究机构和学术中心的应用，最终用户细分可以更清楚地了解市场。这些相互关联的观点不仅完善了市场目标，而且还有助于更深入地了解以患者为中心的需求、临床需求以及治疗方法的整体演变。对于寻求建立有弹性的投资组合和实施有效的打入市场策略的策略家来说，认识这些细分变数至关重要。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球感染疾病和慢性病发生率上升
      • 基因和蛋白质工程的进展
      • 扩大对新型双特异性抗体开发和核准的监管支持
    • 限制因素
      • 双特异性抗体製造的复杂性
    • 机会
      • 个人化治疗方法的新兴趋势
      • 扩大双特异性抗体在治疗罕见疾病的应用
    • 任务
      • 双特异性抗体的安全性和有效性问题
  • 市场区隔分析
    • 作用机转：提高双抗原标标靶化的优先级，以最大限度地减少脱靶效应
    • 治疗领域：扩大双特异性抗体在肿瘤学中的应用，以捕捉和摧毁癌细胞
    • 最终使用者：在医院和专科诊所提供全面的治疗护理
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 双特异性抗体市场（依作用机转）

  • 双抗原标靶
  • 双重阻断抗体
  • T细胞衔接子

第七章双特异性抗体市场（依治疗领域）

  • 自体免疫疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学

第八章双特异性抗体市场（依最终用户）

  • 医院和专科诊所
  • 研究机构和学术中心

9. 美洲双特异性抗体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

10. 亚太地区双特异性抗体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

11. 欧洲、中东和非洲双特异性抗体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Adimab, LLC
  • Affimed GmbH
  • Alligator Bioscience AB
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mereo Biopharma Group PLC
  • Merus NV
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • TG Therapeutics, Inc.
  • Xencor, Inc.
Product Code: MRR-F97DD5A7DF65

The Bispecific Antibodies Market was valued at USD 5.71 billion in 2023 and is projected to grow to USD 7.49 billion in 2024, with a CAGR of 32.64%, reaching USD 41.29 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 5.71 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 41.29 billion
CAGR (%) 32.64%

Bispecific antibodies are rapidly emerging as groundbreaking therapeutic modalities, redefining treatment paradigms across multiple disease areas. In today's environment, where precision and targeted intervention are paramount, these innovative agents stand at the forefront of biomedical science. The science behind designing antibodies that can engage two different antigens simultaneously has advanced considerably, providing superior specificity and potency compared to traditional therapies. This report offers an in-depth analysis of the bispecific antibody market, exploring critical drivers, technological breakthroughs, and evolving market strategies. By examining both clinical advancements and underlying molecular mechanisms, the narrative places the therapeutic potential of bispecific antibodies in a broader context of modern medicine. With a focus on the strategic and operational aspects that influence decision-making, the discussion is tailored for industry experts and key decision-makers looking to understand the impact and future trajectory of this dynamic segment. This comprehensive exploration underscores the immense value and growing market influence of bispecific antibodies in reshaping treatment landscapes across a diverse array of therapeutic applications.

Transformative Shifts in the Landscape

The bispecific antibodies market is undergoing a transformative shift driven by significant advancements that are reshaping both clinical and commercial strategies. Technological innovations have accelerated the discovery and optimization of these complex molecules, ultimately allowing for enhanced engagement with target antigens through refined molecular engineering. Regulatory agencies have also evolved in their approach, balancing expedited pathways to market with stringent safety evaluations to maintain high standards. These shifts are further bolstered by strategic collaborations between pharmaceutical companies and biotechnology innovators, fostering a competitive yet symbiotic ecosystem that accelerates clinical trials and bench-to-bedside transitions. Investment in adaptive clinical design and robust data analytics has illuminated critical efficacy and safety profiles, making it possible for companies to refine patient selection and maximize therapeutic outcomes. This evolving landscape is characterized by the dynamic interplay between scientific discovery, regulatory progression, and market adaptation, underscoring the necessity for stakeholders to remain informed and agile in a rapidly changing environment. By leveraging these transformative shifts, industry leaders are uniquely positioned to harness the full potential of bispecific antibodies and drive meaningful clinical advancements.

Key Segmentation Insights

A detailed segmentation analysis provides a nuanced understanding of the bispecific antibodies market, clarifying avenues for targeted intervention and highlighting growth opportunities. When studying the market based on the mechanism of action, it becomes clear that approaches such as dual antigen targeting, dual-blocking antibodies, and T-cell engagers play pivotal roles in shaping therapeutic efficacy and market dynamics. In parallel, segmentation based on therapeutic area reveals that conditions ranging from autoimmune diseases and infectious diseases to neurological disorders and oncology form the cornerstone of clinical application. This multifaceted approach allows stakeholders to pinpoint segments where unmet needs are highest and potential revenue streams are optimally aligned with emerging clinical evidence. Furthermore, the end-user segmentation delineates the market landscape by distinguishing applications within hospitals and specialist clinics from those pursued in research institutions and academic centers. These interconnected perspectives not only refine market targeting but also foster a deeper understanding of patient-centric needs, clinical demands, and the overall evolution of treatment methodologies. Recognizing these segmentation variables is essential for strategists looking to create a resilient portfolio and implement effective market entry strategies.

Based on Mechanism of Action, market is studied across Dual Antigen Targeting, Dual-Blocking Antibodies, and T-cell Engagers.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Infectious Diseases, Neurological Disorders, and Oncology.

Based on End-user, market is studied across Hospitals & Specialist Clinics and Research Institutions & Academic Centers.

Key Regional Insights

Geographic dynamics play a crucial role in determining market trends and resource allocation in the bispecific antibodies domain. In-depth analysis across various regions reveals distinctive characteristics that influence both product development and adoption rates. The Americas showcase robust infrastructure with thriving biopharmaceutical networks and advanced clinical research facilities that have propelled rapid commercialization. Meanwhile, regions such as Europe, the Middle East, and Africa are witnessing steady growth, supported by comprehensive regulatory reforms and strategic public-private partnerships fostering increased investment in innovative therapies. The Asia-Pacific region, with its burgeoning markets and escalating levels of healthcare expenditure, represents a frontier of potential, driving a surge in clinical research initiatives and collaborative ventures. The integration of region-specific insights with overarching market analysis underscores the importance of tailoring strategies to local nuances while leveraging global industry trends. These regional differentiators not only create diverse investment opportunities but also encourage harmonized regulatory landscapes and drive the broader acceptance of bispecific antibody technologies across varied demographic and economic settings.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, Michigan, Montana, New York, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The bispecific antibodies market is characterized by the active participation of a range of influential companies, each contributing unique technological capabilities and strategic direction. Industry leaders such as AbbVie Inc., Adimab, LLC, and Affimed GmbH continue to drive innovation through focused research and robust clinical development programs. Companies like Alligator Bioscience AB and Amgen Inc. have advanced their portfolios by capitalizing on novel therapeutic modalities to address unmet medical needs. Other major players, including Astellas Pharma Inc. and AstraZeneca PLC, have integrated bispecific approaches into comprehensive treatment strategies, further complemented by the expertise of Bristol-Myers Squibb and Eli Lilly and Company. Notable contributions from Emergent BioSolutions Inc. and F. Hoffmann-La Roche Ltd. have provided clarity in regulatory pathways and clinical trial design, while Genmab A/S and Gilead Sciences, Inc. have leveraged synergistic partnerships to accelerate drug development. Innovent Biologics, Inc., Johnson & Johnson Services, Inc., and Merck KGaA continue to shape the competitive landscape with robust research pipelines. Other recognized companies such as Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc. bring valuable insights and diversified strategies, collectively reinforcing the market's innovation ecosystem.

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Alligator Bioscience AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are urged to harness the transformative trends within the bispecific antibodies market by integrating strategic, research-driven, and patient-focused approaches into their core business models. A comprehensive review of existing portfolios is critical, with companies encouraged to invest in state-of-the-art technologies that facilitate rapid candidate screening and reliable efficacy assessments. Capitalizing on cross-disciplinary partnerships can expedite the translation of novel research findings into clinical applications, thereby bridging the gap between innovation and market readiness. Leaders should also pay careful attention to evolving regulatory frameworks and invest in building agile compliance systems that enable swift adjustments to new guidelines. It is imperative to align R&D strategies with insights derived from detailed segmentation analyses, ensuring that therapeutic development is both targeted and adaptive. Dedicated initiatives to nurture talent in emerging fields, coupled with an emphasis on robust clinical trial designs, can further strengthen a company's market positioning. By adopting these actionable recommendations, decision-makers can not only mitigate risks but also drive sustainable growth, fortifying their competitive edge in a rapidly advancing therapeutic landscape.

Conclusion: Charting the Future of Bispecific Antibodies

In summary, the bispecific antibodies market is at a pivotal juncture, where rapid technological advances meet unmet clinical needs. The extensive segmentation analysis, coupled with evolving regional trends and significant contributions from leading companies, paints a comprehensive picture of a dynamic and promising therapeutic landscape. With transformative shifts in market paradigms and a clear delineation of strategic opportunities, stakeholders are well-positioned to propel innovation and optimize patient outcomes. The interplay between science, regulatory action, and market dynamics creates a fertile ground for sustained growth and renewed confidence from investors and clinicians alike. As companies fine-tune their strategies to harness these emerging opportunities, the future of bispecific antibodies looks set to redefine conventional treatment methodologies and offer unprecedented clinical benefits. This conclusion not only celebrates current achievements but also serves as a clarion call for further research, investment, and strategic alignment in this fast-evolving market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious and chronic illnesses globally
      • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
      • 5.1.1.3. Growing regulatory support for the development and approval of novel bispecific antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the manufacturing of bispecific antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend toward personalized therapeutic approaches
      • 5.1.3.2. Expanding usage of bispecific antibodies in the treatment of rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with the safety and efficacy of bispecific antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
    • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
    • 5.2.3. End-user: Provision of comprehensive therapeutic care in hospitals and specialist clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bispecific Antibodies Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Dual Antigen Targeting
  • 6.3. Dual-Blocking Antibodies
  • 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Infectious Diseases
  • 7.4. Neurological Disorders
  • 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals & Specialist Clinics
  • 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Merck & Co Inc expands oncology portfolio with acquisition of novel bispecific antibody for B-cell malignancies
    • 12.3.2. Novartis collaborates with Dren Bio, for innovative bispecific antibodies to revolutionize cancer treatments
    • 12.3.3. Johnson & Johnson's Acquisition of Numab Therapeutics Boosting Bispecific Antibody Pipeline
    • 12.3.4. Regeneron highlights promising anti-tumor activity of novel bispecific antibody REGN7075
    • 12.3.5. Zenas Biopharma raises USD 200 Million in Series C Funding
    • 12.3.6. Invenra and Astellas Pharma form strategic partnership to enhance bispecific antibody R&D using the B-Body platform
    • 12.3.7. Biotheus and Hansoh Pharma expand partnership to develop innovative bispecific antibody-drug conjugates for cancer treatment
    • 12.3.8. FDA approves Johnson & Johnson's TECVAYLI for biweekly dosing in multiple myeloma
    • 12.3.9. AstraZeneca advances cancer treatment with innovative bispecific antibodies targeting multiple tumor antigens
    • 12.3.10. Janssen's TALVEY talquetamab-tgvs receives FDA accelerated approval
    • 12.3.11. FDA greenlights AbbVie and Genmab's EPKINLY for relapsed or refractory DLBCL
    • 12.3.12. Pfizer's elranatamab receives priority review by US FDA and EMA with positive trial results
  • 12.4. Strategy Analysis & Recommendation
    • 12.4.1. AbbVie Inc.
    • 12.4.2. AstraZeneca PLC
    • 12.4.3. F. Hoffmann-La Roche Ltd.
    • 12.4.4. Amgen Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adimab, LLC
  • 3. Affimed GmbH
  • 4. Alligator Bioscience AB
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bristol-Myers Squibb
  • 9. Eli Lilly and Company
  • 10. Emergent BioSolutions Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Genmab A/S
  • 13. Gilead Sciences, Inc.
  • 14. Innovent Biologics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Mereo Biopharma Group PLC
  • 18. Merus N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Pieris Pharmaceuticals, Inc.
  • 22. Regeneron Pharmaceuticals Inc.
  • 23. Sanofi S.A.
  • 24. TG Therapeutics, Inc.
  • 25. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. BISPECIFIC ANTIBODIES MARKET MULTI-CURRENCY
  • FIGURE 2. BISPECIFIC ANTIBODIES MARKET MULTI-LANGUAGE
  • FIGURE 3. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 4. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023